On April 3, 2024, the Company and Samsung BioLogics Co., Ltd. ("Samsung") executed an agreement (the "Letter Agreement"), wherein the parties reached agreement for an orderly process for winding down…
In January 2026, pursuant to a Standby Equity Purchase Agreement (the “SEPA”) entered into on November 3, 2025, between the Company and YA II PN, Ltd., a Cayman Islands exempt limited partnership (“Y…
On January 10, 2024, the Company entered into an agreement with an executive services firm to engage Mitchell Cohen to provide financial and accounting services to the Company as an independent contractor
The Company has agreed to pay 20% of its qualifying Revenue generated in each calendar year, if any, with such payments to be applied to the return of the Company's cash collateral in the amount of $…
On January 26, 2024, the Company entered into an employment agreement with Jacob P. Lalezari, M.D., under which he is serving as the Company's Chief Executive Officer
In March 2023, the Company entered into a joint development agreement with a third-party generative artificial intelligence ("AI") drug discovery and development company to develop one or more longer…
